Who are OROS MPH's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): OROS MPH Tablets, Active bupropion + counseling, drops intilation (Taponoto ® ), Drug: PRC-063.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oros-mph.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

OROS MPH — Competitive Intelligence Brief

OROS MPH (OROS MPH) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Central nervous system stimulant; dopamine-norepinephrine reuptake inhibitor. Area: Psychiatry / Neurology.

marketed Central nervous system stimulant; dopamine-norepinephrine reuptake inhibitor Dopamine transporter (DAT); norepinephrine transporter (NET) Psychiatry / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

OROS MPH (OROS MPH) — Ortho-McNeil Janssen Scientific Affairs, LLC. OROS MPH is an extended-release formulation of methylphenidate that provides sustained dopamine and norepinephrine reuptake inhibition throughout the day.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
OROS MPH TARGET	OROS MPH	Ortho-McNeil Janssen Scientific Affairs, LLC	marketed	Central nervous system stimulant; dopamine-norepinephrine reuptake inhibitor	Dopamine transporter (DAT); norepinephrine transporter (NET)
OROS MPH Tablets	OROS MPH Tablets	Ortho-McNeil Janssen Scientific Affairs, LLC	marketed	Central nervous system stimulant; dopamine-norepinephrine reuptake inhibitor	Dopamine transporter (DAT); norepinephrine transporter (NET)
Active bupropion + counseling	Active bupropion + counseling	University of Wisconsin, Madison	marketed	Antidepressant (dopamine-norepinephrine reuptake inhibitor)	Dopamine transporter (DAT), Norepinephrine transporter (NET)
drops intilation (Taponoto ® )	drops intilation (Taponoto ® )	Hospital Clinic of Barcelona	marketed	Dopamine-norepinephrine reuptake inhibitor
Drug: PRC-063	Drug: PRC-063	Rhodes Pharmaceuticals, L.P.	phase 3	Stimulant; dopamine-norepinephrine reuptake inhibitor	Dopamine transporter (DAT); norepinephrine transporter (NET)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Central nervous system stimulant; dopamine-norepinephrine reuptake inhibitor class)

Ortho-McNeil Janssen Scientific Affairs, LLC · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). OROS MPH — Competitive Intelligence Brief. https://druglandscape.com/ci/oros-mph. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab